MERREM I.V. – Susceptibility

Learn about pathogens covered by MERREM I.V.

• Power against gram-negatives
• Power against gram-positives
• Power against anaerobes

In vitro activity does not necessarily correlate with clinical effectiveness.

MERREM I.V. is indicated as a single-agent therapy from the treatment of complicated appendicitis and peritonitis, complicated skin and skin structure infections, and pediatric (≥ 3 months of age) bacterial meningitis, when caused by susceptible isolates of indicated pathogens.

* Data from clinical isolates, 1999-2001.
† Data from a survey of medical centers representing various US geographical areas, 2000.
‡ Data from US MYSTIC database 2005.
§ Data from the SENTRY Program 2000, which collected isolates from 30 medical centers in North America (US, 25; Canada, 5).
II Beta-lactamase and non-beta-lactamase-producing, methicillin-susceptible isolates only.

Next Page > Gram-Negatives